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Background The Arg399Gln polymorphism in the X‐ray repair cross‐
complementing group 1 gene (XRCC1) may alter the risk of prostate cancer (PCa).
The present study aimed to investigate the association of the XRCC1‐Arg399Gln poly-
morphism with PCa risk in an Iranian population, as followed by a meta‐analysis and
an in silico analysis.
Methods In a case–control study, 360 subjects were included (180 men with PCa
and 180 healthy controls). XRCC1‐Arg399Gln genotyping was performed using the
polymerase chain reaction‐restriction fragment length polymorphism method. In the
meta‐analysis, 14 eligible studies were included to which our case–control data were
added to estimate the pooled odds ratios. Some bioinformatics tools were employed
to evaluate the effects of Arg399Gln substitution on molecular aspects of the XRCC1
protein.
Results Our case–control study revealed a significant association between the
XRCC1‐Arg399Gln polymorphism and PCa risk. The data from overall meta‐analysis
showed significant associations between the mentioned polymorphism and PCa risk
in allelic and recessive genetic models. In addition, we observed statistically significant
associations in stratified analyses by ethnicity, sample size and source of controls. Our
in silico analysis showed that Arg399Gln substitution could be damaging with respect
to the function and structure of the XRCC1 protein.
Conclusions Based on these results, the XRCC1‐Arg399Gln polymorphism might be
a risk factor for PCa and it could be considered as a prognostic and predictive
biomarker for susceptible men.
KEYWORDS
in silico analysis, meta‐analysis, prostate cancer, XRCC1 gene1 | INTRODUCTION
Prostate cancer (PCa) is amongst the most common cancers among
males.1 This cancer is the second cause of death of males and its
occurrence increases with an increase in age.2 Although previouswileyonlinelibrary.com/journastudies have been shown that diet, cigarette smoking, race, infection
and ultraviolet light could increase PCa, the exact cause of PCa
remains unclear.3,4 Despite possessing these risk factors, PCa might
not occur, which could be a result of the presence of genetic factors.
Thus genetic factors in combination with environmental players are© 2018 John Wiley & Sons, Ltd.l/jgm 1 of 8
2 of 8 NOUREDDINI ET AL.involved in the development of PCa.5,6 Malignant transformation of
prostate cells is always associated with genetic alterations such as
deletions, inversion and point mutations.7 The association between
genetic factors such as several single nucleotide polymorphisms
(SNPs) with various cancers such as PCa, leukemia, colorectal cancer,
breast cancer, and so on, has been reported.8-11 Several lines of inves-
tigations have shown the relationship between SNPs of the genes
involved in DNA repair and cancer susceptibility. Repair capacity of
DNA is also involved in pathogenesis of PCa.8,12,13
The X‐ray repair cross‐complementing group 1 gene (XRCC1),
located on chromosome 19 (19q13) with 17 exons, plays a fundamen-
tal role in DNA repair.14 This gene encodes a protein with 633 amino
acids that plays an essential role in repair of mutated DNA. Arg280His
(ID: rs25489) and Arg399Gln (ID: rs25487) are two common variations
of XRCC1 gene. The functional impacts of these polymorphism have
not been fully understood. Based on the SNP database of the NCBI,
the Arg280His variation is a three‐allelic (A/C/G) polymorphism.13
Several reports have indicated that the Arg399Gln polymorphism is
a risk factor for Pca, although some controversy remains.15-19 Prostate
malignancy is a disorder in elderly men and its occurrence is increasing
in Iran.20 To our knowlege, no studies have investigated the associa-
tion of XRCC1 gene polymorphisms with PCa risk in Iranian popula-
tion. Thus, we aimed to evaluate the association between Arg399Gln
polymorphism and PCa in a case–control study. Then, the genetic
association of this polymorphism with PCa would be evaluated via a
meta‐analysis. Finally, the effects of this polymorphism on the struc-
ture and function of the XRCC1 protein would be assessed using bio-
informatics tools.2 | MATERIALS AND METHODS
2.1 | Case–control study
The present study comprised a case–control study. We recruited 180
PCa subjects and 180 controls from Kashan city (Isfahan province,
Iran) between 2014 and 2016. The PCa participants were histopatho-
logically confirmed as PCa at the Shahid Beheshti hospital. The healthy
subjects were randomly selected from men who referred to the same
hospital for health check‐up. Control subjects with serum prostate‐
specific antigen (PSA) > 2.5 ng/ml were excluded from the study.
Written informed consent was obtained from all subjects. Finally,
2 ml of blood was collected from all participants into complete blood
count tubes containing the anticoagulant ethylenediaminetetracetic
acid. The research protocols and experimental tests were approved
by the Medical Ethic Committee of the Research Council of Kashan
University of Medical Sciences in December 2016 (Ref no. 95103).
DNA extraction from blood samples was performed by DNGplus
(CinnaGen, Tehran, Iran) in accordance with a standard protocol.
XRCC1‐Arg399Gln SNP genotyping was performed by the polymerase
chain reaction‐restriction fragment length polymorphism (PCR‐RFLP)
method. Accordingly, the total XRCC1 gene sequence was obtained
from NCBI. The Arg399Gln polymorphic region was detected on the
XRCC1 gene and then specific primers were designed using Oligo7
software (https://www.oligo.net). The sequences of the forward andreverse primers were 5′‐CCTCAGATCACACCTAACTGGC‐3′ and 5′‐
CTAACACTTGTTCTCCCACCCC‐3′, respectively. PCR was carried
out in total volume of 25 μl containing 12.5 μl of PCR Master Mix
(2×), each primer at a concentration of 0.5 μM and 50 ng of DNA tem-
plate. PCR was performed in a peqSTAR thermal cycler (PeqLab,
Erlangen, Germany) with the program: initial denaturation in 94°C
for 5 min, with 35 repetitive cycles containing a denaturation step at
94°C for 45 s, an annealing step at 58°C for 45 s, and an extension
step at 72°C for 45 s, which was followed by extension in 72°C for
7 min. All of the PCR reagents were obtained from Fermentas (Sankt
Leon‐Rot, Germany). Amplified fragments were treated by MspI
(Fermentas) restriction enzyme using a standard protocol. Finally, the
digested mixtures were electrophoresed on 1% agarose gel for geno-
type detection. The samples with the AA genotype showed a 440‐bp
fragment on the agarose gel. Samples with the GG genotype show
two 158‐ and 282‐bp fragments, whereas the GA genotype revealed
three 440‐, 158‐ and 282‐bp fragments on the agarose gel. To confirm
the PCR‐RFLP procedure, some samples with different genotypes
were sequenced by CinnaGen.2.2 | Meta‐analysis
An electronic search was condicted utilizing the PubMed, EMBASE,
Google Scholar and ScienceDirect databases (dated up to 20 October
2017) by two of the researchers independently. Keywords, including
X‐ray repair cross‐complementing or XRCC1, and SNP or polymor-
phism or mutation or variants, and prostate cancer, were used to iden-
tify relevant articles. Also, the references of collected articles were
revised to find possible eligible studies. Eligible studies had to meet
the inclusion criteria: (i) case–control studies with the human origin
designed to examine the association of XRCC1‐Arg399Gln with PCa
risk and (ii) existing data on the genotype frequencies in both cases
and controls. Two two of the researchers independently screened
and selected eligible studies with respect to the final meta‐analysis.
Disagreements were solved by consultation. For the next step, the rel-
evant data were extracted from all of the included studies.2.3 | In silico analysis
The effects of Arg399Gln substitution on the XRCC1 protein were
evaluated using bioinformatics tools. First, the peptide sequence of
XRCC1 was deduced from the ExPASy database (https://www.
expasy.org) and the location of the Arg399Gln polymorphism was
determined on the XRCC1 sequence. The impact of Arg399Gln on
the physicochemical characteristics of the protein was evaluated using
the ProtParam webserver (https://web.expasy.org/protparam). The
effects of the substitution on the secondary structure of protein were
assessed by the Chou–Fasman method. Then, the FASTA sequence of
the mentioned peptide was converted to Protein Databank format for
both wild and mutant protein using the PHYRE2 protein fold recogni-
tion server (www.sbg.bio.ic.ac.uk/phyre2).21 The Ramachandran and
hydrophobicity plots were obtained using Discovery Studio Visualiza-
tion – Accelrys software (http://accelrys.com/products/collaborative‐
science/biovia‐discovery‐studio). In addition, the molecular effects of
Arg399Gln substitution on protein function were evaluated using
TABLE 1 Demographic and clinical features of study population
Variables Case (n = 180) Control (n = 180) p value
NOUREDDINI ET AL. 3 of 8the Polyphen2 webserver (genetics.bwh.harvard.edu/pph2) for both
HumDiv and HumVar models.22Age (years)
Range 41–86 51–88
Mean ± SD 64.73 ± 12.28 66.67 ± 7.46 0.071
BMI (kg/m2)
Mean ± SD 23.08 ± 2.72 23.63 ± 2.55 0.051
Total PSA (ng/ml)
Mean ± SD 110.51 ± 57.64 1.25 ± 0.75 <0.0001
Smoking
Yes 112 123 0.223
No 68 57
Gleason grade
< 7 50 ‐ ‐
7 41 ‐ ‐
> 7 89 ‐ ‐
BMI, body mass index.2.4 | Statistical analysis
In the case–control study, a chi‐squared test was used to evaluate
Hardy–Weinberg equilibrium (HWE), differences in allele and geno-
type frequencies, and other qualitative variables between case and
control groups. Association of the XRCC1‐Arg399Gln polymorphism
with the risk of PCa was estimated by odds ratios (ORs) with 95% con-
fidence intervals (95% CI). In addition, an independent t‐test was used
to compare numerical variables between case and control groups.
p < 0.05 was considered statistically significant. These analyses were
performed using SPSS, version 19 (IBM Corp., Armonk, NY, USA).
In the meta‐analysis, the pooled data were employed to evaluate
the strength of the association of XRCC1‐Arg399Gln SNP with PCa
risk by utilizing ORs with 95% CIs in five allelic (G versus A), homozy-
gote co‐dominant (GG versus AA), heterozygote co‐dominant (AG ver-
sus AA), dominant (AG + GG versus AA) and recessive (GG versus AA
+AG) genetic models. Moreover, a stratified meta‐analysis was per-
formed for ethnicity, sample size, source of control and HWE status.
Heterogeneity among the included studies was evaluated by I2 score
and a chi‐square‐based Q‐statistic test, with p > 0.10 being considered
statistically significant. In these cases, the ORs were pooled in a ran-
dom‐effects model; otherwise, the fixed‐effects model was
employed.23,24 Potential publication bias was evaluated by funnel
plots and Egger's regression test. In addition, a sensitivity examination
was performed to measure the stability of the association results.
These analyses were performed using Open Meta Analyst (www.
cebm.brown.edu/openmeta) and Comprehensive Meta‐Analysis
(https://www.meta‐analysis.com) software.3 | RESULTS
3.1 | Case–control analysis
Some demographic and clinical features of the study population are
shown in Table 1. We found no statistically significant differences
for body mass index, age and smoking status between the case and
control groups. Furthermore, Gleason scores and PSA levels are
shown in Table 1.
We calculated the power of our study with regard to the domi-
nant model (AG + GG versus AA) and this was estimated to be more
than 80%. The distribution of the genotype and allele frequencies of
the case–control study is shown in Table 2. The genotype distribution
revealed that HWE remains in both the case (χ2 = 0.023, p = 0.879)
and control (χ2 = 1.111, p = 0.292) groups. The genotype analysis
revealed that AG (OR = 1.82, 95% CI = 1.17–2.83, p = 0.008) and
GG (OR = 2.12, 95% CI = 1.04–4.34, p = 0.040) genotypes are associ-
ated with PCa risk in our study population. Moreover, carriers of the G
allele are at high risk for PCa (OR = 1.87, 95% CI = 1.23–2.85,
p = 0.003). Allele analysis showed that there is a significant association
between the G allele and PCa risk (OR = 1.60, 95% CI = 1.16–2.20,
p = 0.004).3.2 | Meta‐analysis
Eighty‐one relevant papers were identified by the charted search
strategy. In accordance with the inclusion criteria, 16 sets of data from
fourteen articles1-5,15-19,25-28 were selected for meta‐analysis. Then,
our case–control data were added to the meta‐analysis. A flow dia-
gram of the study selection procedure and exact causes for exclusions
is shown in Figure 1. In total, 8662 subjects including 4307 cases of
PCa and 4355 healthy controls, were included in the meta‐analysis.
The year of publication ranged from 2002 to 2012. Details of eligible
studies, including ethnicity, sample size, allele and genotype frequen-
cies, pHWE of control groups, source of controls, and genotyping
method, are provided in Table 3. Among all of the studies, one study
did not separate GG and AG genotypes.2 In addition, two studies did
not report the ethnicity of their population studies.2,25 Furthermore,
two studies investigated both Caucasian and African‐American
populations.1,19
An assessment of the association between the XRCC1‐Arg399Gln
polymorphism and PCa risk is provided in Table 4. Through the overall
analyses, significant associations were observed between XRCC1‐
Arg399Gln and PCa susceptibility in allelic (OR = 1.19, 95% CI = 1.070–
1.32, p = 0.001) and recessive (OR = 1.15, 95% CI = 1.04–1.28,
p = 0.007) models (Figure 2). Stratified analysis by ethnicity indicated
a significant increased risk for PCa in Caucasian population (G versus
A: OR = 1.22, 95% CI = 1.01–1.48, p = 0.039). Also, stratified analysis
by sample size revealed a significant association between Arg399Gln
and PCa in studies with a sample size smaller (GG versus AA+AG:
OR = 1.22, 95% CI = 1.04–1.45, p = 0.017) or greater (G versus A:
OR = 1.32, 95% CI = 1.13–1.55, p < 0.001) than 400 subjects. More-
over, stratified analysis by source of controls showed a significant asso-
ciation between Arg399Gln and PCa in studies with population‐ (GG
versus AA+AG: OR = 1.14, 95% CI = 1.01–1.29, p = 0.028) and hospi-
tal‐based (G versus A: OR = 1.29, 95% CI = 1.13–1.48, p < 0.001) con-
trol subjects. When a study with a pHWE of control group less than
0.0518 was removed from the meta‐analysis, we observed a significant
association between the polymorphism and PCa in allelic (OR = 1.19,
FIGURE 1 Flow chart of the study selection
TABLE 2 Genotype and allele frequencies of the XRCC1‐Arg399Gln in case and control groups
Genotype/allele
n (%)
OR (95% CI) p valueControl (n = 180) Case (n = 180)
AA 101 (56.11%) 73 (40.55%) ‐ ‐
AG 64 (35.56%) 84 (46.67%) 1.82 (1.17–2.83) 0.008
GG 15 (8.33%) 23 (12.78%) 2.12 (1.04–4.34) 0.040
AG + GG 79 (43.00%) 107 (59.45%) 1.87 (1.23–2.85) 0.003
A 266 (73.89%) 230 (63.89%) ‐ ‐
G 94 (26.11%) 130 (36.11%) 1.60 (1.16–2.20) 0.004
Significant differences between case and controls are shown in bold.
4 of 8 NOUREDDINI ET AL.95% CI = 1.06–1.32, p = 0.003) and recessive (OR = 1.16, 95%
CI = 1.05–1.30, p = 0.006) models. Overall, there were true inter‐study
heterogeneities in allelic (pheterogeneity = 0.009, I
2 = 50%), homozygote
co‐dominant (pheterogeneity = 0.071, I
2 = 37%), homozygote co‐dominant
(pheterogeneity < 0.001, I
2 = 62%) and dominant (pheterogeneity > 0.001,
I2 = 88%) models. Similarly, heterogeneities remained in the stratified
analyses (see Supporting information, Table S1).
For overall and stratified analyses, the funnel plots appeared to be
symmetric in all genetic models (for allelic and recessive models,
Figure 2). Also, we did not observe any publication bias using Egger's
test (see Supporting information, Table S1). We evaluated the strength
of the pooled ORs by removing a study at each analysis. No significant
change of the pooled ORs was observed when each of the studies was
omitted (data not shown). These results show that our meta‐analysis
was exactly robust.3.3 | Structural analysis
Some bioinformatics tools were employed to evaluate the effects of
Arg399Gln on molecular aspects of the XRCC1 protein. The data from
ProtParam revealed that the molecular weights of wild and mutant
types of XRCC1 were 69497.53 and 69525.59 Da, respectively.Theoretical pI was predicted to be 5.93 and 6.02 for wild and mutant
proteins, respectively. The instability index was computed to be 63.35
for the 399Gln phenotype and 64.25 for 399Arg. Furthermore, the ali-
phatic index of wild and mutant proteins was predicted to be 62.89.
This polymorphism could alter hydrophobicity and the Ramachandran
plots of XRCC1 (see Supporting information, Figure S1). The location
of the Arg399Gln polymorphism was predicted on a helix domain in
the three‐dimensional structure of XRCC1 (Figure 3). The effects of
Arg399Gln on the secondary structure of XRCC1 were evaluated by
the Chou–Fasman method. As shown in Figure 3, Arg399Gln substitu-
tion could change the secondary structure of XRCC1 around the men-
tioned polymorphism. The data from the Polyphen2 webserver
showed that Arg399Gln substitution is probably damaging for both
HumDiv (score = 0.979; sensitivity = 0.76; specificity = 0.96) and
HumVar (score = 0.536; sensitivity = 0.82; specificity = 0.82) models
(see Supporting information, Figure S2).4 | DISCUSSION
In the present study, we first evaluated the association of XRCC1‐
Arg399Gln with PCa in an Iranian population. Our data revealed that
there is a significant association between the mentioned SNP and
PCa risk. However, there are some studies with inconsistent results
in this regard. For example, Hamano et al.16 reported that there is no
significant association between XRCC1‐Arg399Gln and PCa risk,
whereas Berhane et al.4 reported significant associations. Therefore,
we performed a meta‐analysis with the existing publications in this
area to obtain a more accurate conclusion. The results of the meta‐
analysis demonstrated significant associations between Arg399Gln
and PCa risk. Heterogeneity analysis revealed true heterogeneities
among the studies included in the meta‐analysis. Therefore, we
employed a random‐effects model with a wider confidence interval
to calculate pooled ORs. Differences between the results of individual
studies may arise from the sample size and the different ethnic origin
of the people included in the cited articles, as well as geographical and
environmental factors. A meta‐analysis revealed there was no publica-
tion bias. Also, after the sensitivity test, no significant change of the
pooled ORs was found. Such evidence indicates that the results of
the meta‐analysis are robust and reliable.
DNA repair mechanisms play a crucial role in the repair of multiple
DNA damage triggered by exogenous or endogenous causes, such as
single‐strand breaks, oxidative DNA damage, non‐bulky adducts or
T
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TABLE 4 Association results in the meta‐analysis
Group
G versus A GG versus AA AG versus AA AG + GG versus AA GG versus AA + AG
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Total 1.19 (1.070–1.32) 0.001 1.07 (0.87–1.30) 0.530 0.93 (0.76–1.13) 0.447 0.94 (0.69–1.26) 0.663 1.15 (1.04–1.28) 0.007
Asian 1.13 (0.96–1.34) 0.135 1.01 (0.67–1.53) 0.957 0.78 (0.52–1.18) 0.241 0.91 (0.64–1.30) 0.620 1.19 (0.99–1.43) 0.064
Caucasian 1.22 (1.01–1.48) 0.039 1.17 (0.94–1.46) 0.158 1.12 (0.92–1.37) 0.268 0.95 (0.53–1.69) 0.849 1.12 (0.98–1.28) 0.094
African‐
American
1.12 (0.78–1.60) 0.551 0.95 (0.29–3.11) 0.934 0.96 (0.55–1.69) 0.894 0.98 (0.569–1.69) 0.945 1.31 (0.76–2.27) 0.326
Sample
size<400
1.12 (0.98–1.28) 0.111 1.03 (0.76–1.40) 0.830 0.83 (0.63–1.11) 0.203 0.95 (0.74–1.21) 0.653 1.22 (1.04–1.45) 0.017
Sample
size>400
1.32 (1.13–1.55) < 0.001 1.10 (0.84–1.44) 0.496 1.08 (0.84–1.38) 0.540 0.97 (0.54–1.72) 0.903 1.11 (0.97–1.27) 0.117
PB 1.13 (0.99–1.29) 0.083 0.97 (0.71–1.31) 0.831 0.82 (0.59–1.12) 0.208 0.83 (0.52–1.33) 0.443 1.14 (1.01–1.29) 0.028
HB 1.29 (1.13–1.48) < 0.001 1.17 (0.91–1.50) 0.227 1.04 (0.80–1.35) 0.773 1.10 (0.87–1.39) 0.444 1.19 (0.97–1.47) 0.101
PHWE
> 0.05
1.19 (1.06–1.32) 0.003 1.11 (0.91–1.36) 0.316 0.97 (0.79–1.18) 0.733 0.96 (0.70–1.32) 0.806 1.16 (1.05–1.30) 0.006
PB, population‐based; HB, hospital‐based.
FIGURE 2 Forest and funnel plots. A, Forest plot for the association of the Arg399Gln polymorphism of the XRCC1 gene with PCa in allelic (left)
and recessive (right) models. B, Funnel plot for the association of the Arg399Gln polymorphism of the XRCC1 gene with PCa in allelic (left) and
recessive (right)
6 of 8 NOUREDDINI ET AL.alkylation and methylation.5,25 Mutations in some genes that cause a
deficiency or an absence of DNA repair protein functions can result
in a DNA repair deficit.25 Among the mutations that increase the risk
of PCa, polymorphisms comprise a large proportion.3 Many studies
confirm that SNPs in DNA repair genes can increase the risk of DNA
damage and cancer.6,8,12,29 The four most important DNA repair
mechanisms are base excision repair, nucleotide excision repair, dou-
ble‐strand break repair and mismatched repair.13 Base excision repair
eliminates small lesions containing oxidized or reduced bases,
fragmented and non‐bulky adducts or those created by methylation.
Nucleotide excision repair eliminates larger lesions that are usuallycaused by exogenous or environmental damage. Double‐strand break
repair, which is more difficult compared to other repairs, corrects rep-
lication errors or exogenous causes such as ionizing radiation. The last
DNA repair mechanism is mismatched repair, which adjusts replication
errors (base–base or insertion–deletion mismatch) resulting in DNA
polymerase mistakes.12,13 The X‐ray repair cross‐complementing
group 1 gene as a DNA repairing gene can interact with numerous
important repair proteins, playing an essential role in base excision
repair and the repair of single‐strand breaks of DNA, and also exhibits
polymorphic variations.15 Among several polymorphisms that are
known in the XRCC1 gene, Arg399Gln has been associated with
FIGURE 3 Three‐dimensional and
secondary structures of XRCC1 around the
Arg399Gln substitution. A, Arg399Gln
substitution is located on a helix region. B,
Partial secondary structure of XRCC1 for
399Gln (up) and 399Arg (down) phenotypes.
Changes in secondary structure are indicated
by a red box
NOUREDDINI ET AL. 7 of 8reduced DNA repair capacity.1 Indeed, the special effects of this poly-
morphism in XRCC1 are not well recognized, although it is probable
that Arg399Gln may be associated with unregulated cell growth and
carcinogenesis.13 There are two C‐terminal BRCT domains that
interact with DNA ligase III alpha. The Arg399Gln SNP is located on
the first BRCT domain.30,31 Therefore, this SNP may affect
heterodimerization of the protein with DNA ligase III.
According to our previous studies and to clarify the molecular
aspects of Arg399Gln substitution on the XRCC1 protein, we used
bioinformatics tools.32,33 In silico analysis provides a time‐ and cost‐
consuming way of analyzing coding and non‐coding SNPs.34-36 Our
bioinformatics analysis indicated that the Arg399Gln polymorphism
is a damaging variation. This SNP could change the instability index
of the protein, which would have an influence on protein activity.37
This result was consistent with the Polyphen2 output that reported
Arg399Gln to be a damaging SNP. The PolyPhen‐2 webserver indi-
cates the likely influence of coding SNPs on the stability and function
of proteins. It assesses the potential damaging impacts of the non‐syn-
onymous SNPs based on a functional interpretation of SNPs and maps
coding SNPs, as well as some other outlines. This server is also related
to the UCSC database (https://genome.ucsc.edu).22
In conclusion, the results of the present study suggest that the
XRCC1‐Arg399Gln polymorphism could be as a prognostic and
predictive biomarker for Pca, especially in a Caucasian population.
There are some limitations to the present study that should be men-
tioned. In our case–control study, we did not consider gene–gene
and gene‐environmental interactions. Also, it would be too better to
analyze the case–control study in a larger sample size with different
ethnicities. In our meta‐analysis, we did not access original data suchas the clinical characteristics of participants to adjust our calculations.
Because tumor features have not been taken into account, it is prob-
able that some gene variations impact upon the tumor features in a
manner that may pose a genetic risk factor for other disorder features.
Also, there were no studies relating to an African population that
would improve our meta‐analysis.
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